title: A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis.
abstract: Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30-40% of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
authors.affiliation: Department of Oncology, Faculty of Medicine, McGill University and Lady Davis Medical Research Institute, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Mira
authors.initials: M
authors.lastname: Ghaly
authors.affiliation: Department of Oncology, Faculty of Medicine, McGill University and Lady Davis Medical Research Institute, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Corin
authors.initials: C
authors.lastname: Seelemann
authors.affiliation: Department of Oncology, Faculty of Medicine, McGill University and Lady Davis Medical Research Institute, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Arezu
authors.initials: A
authors.lastname: Jahani-Asl
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002817:Chordoma / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors
keywords: EGFR inhibitors; MET inhibitors; chordoma; compound drug screen; crizotinib; met; sapitinib